Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
RESEARCH TOOLSreports
Holding ITRM?
Track your performance easily
Earnings Data
Report Date
Mar 31, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.17Last Year’s EPS
-$0.81Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 23.78%
|Next Earnings Date:Mar 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted the significant milestone of receiving FDA approval for ORLYNVAH, along with strong market exclusivity and patent protection. While there were substantial reductions in operating expenses, the increase in net loss and outstanding debts are concerns. Overall, the call leans positively due to the strategic advancements and financial planning to extend the cash runway.Company Guidance
During the Iterum Therapeutics third-quarter 2024 earnings call held on November 14, 2024, key metrics and guidance were discussed concerning the company's financial position and future outlook. The company reported total operating expenses of $4.9 million for Q3 2024, significantly down from $16.7 million in Q3 2023, primarily due to reduced research and development expenses. Net loss on a GAAP basis was $6.1 million, compared to $3.9 million in the previous year, while on a non-GAAP basis, the net loss was $4.8 million, a decrease from $15.7 million in Q3 2023. Iterum expects to fund its operations into 2025, including the repayment of $11.1 million of exchangeable notes due January 31, 2025. The company also highlighted the recent FDA approval of ORLYNVAH, which has been granted 10 years of market exclusivity under the GAIN Act, extending to 2034, with U.S. patent protection secured until 2039. Additionally, Iterum discussed its strategic efforts to maximize the value of ORLYNVAH through potential partnerships or transactions.FDA Approval for ORLYNVAH
Received FDA approval for ORLYNVAH, an oral sulopenem product for treating uncomplicated urinary tract infections, marking the first U.S. approval of an oral product in the penem class.
Market Exclusivity and Patent Protection
ORLYNVAH has 10 years of market exclusivity under the GAIN Act and patent protection until 2039 in the U.S., which includes method of use and composition of matter.
Significant Decrease in Operating Expenses
Total operating expenses decreased from $16.7 million in Q3 2023 to $4.9 million in Q3 2024, primarily due to lower R&D costs following the completion of the REASSURE trial.
Cash Runway Extended
The company expects to fund operations into 2025, including the repayment of exchangeable notes due January 31, 2025.
---
ITRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ITRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.43 | $1.36 | -4.90% |
| Aug 14, 2024 | $1.17 | $1.21 | +3.42% |
| May 13, 2024 | $1.55 | $1.52 | -1.94% |
| Mar 28, 2024 | $1.59 | $1.54 | -3.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Iterum Therapeutics Plc (ITRM) report earnings?
Iterum Therapeutics Plc (ITRM) is schdueled to report earning on Mar 31, 2025, TBA Not Confirmed.
What is Iterum Therapeutics Plc (ITRM) earnings time?
Iterum Therapeutics Plc (ITRM) earnings time is at Mar 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ITRM EPS forecast?
ITRM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.17.
---